Ann: Proteomics International raises $6m in successful Placement, page-5

The key take aware here is use of funds – “Manufacture & up-scaling of reagent inventory for the PromarkerD predictive test.”

With an average annual burn of $4M with approx. $2M already on hand, this gives us the company a good 12month runway. We should be well advanced in our FDA registration as well CPT completion.

Endometriosis stage 2 study with larger cohort is in the works as well potential commercialization options for oxidative stress 2-tag biomarkers. QIMR oesophageal cancer, Giardia, COPD, COVID should all get some news within the next 12 months too. PromarkerD IP (Patent and Trademark) covers 272M diabetics, if PromarkerD becomes standard of care to measure DKD progression (which Janssen stage 2 is all about) that’s a significant revenue stream.

Royalty based ranging 5-15% per test priced at 50-150USD. Also very nice to see that company is now actively targeting key opinion leaders to promote the test, with immunoassay version of the test this is starting to become an inflection point for PromarkerD.

Next 12 months have some key defining moments for the company.